GHK-Cu (Copper Peptide)

What Is GHK-Cu? The Copper Complex Isolated in 1973

UKPWritten & reviewed by William Heath · Editor, UK Peptides research library2 min readLast reviewed 2026-08-294 cited sources

The short answer

GHK-Cu is a copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, first isolated from human plasma albumin fraction by Loren Pickart in 1973. The free peptide has a molecular weight of 340.38 Da; the copper complex is 402.92 Da, the difference being copper bound in place of a displaced proton.

Key facts

Peptide sequence
Gly-His-Lys (GHK)
Free peptide MW
340.38 Da (C14H24N6O4)
Copper complex MW
402.92 Da (C14H23CuN6O4+)
GHK CAS
49557-75-7
GHK-Cu CAS
89030-95-5
PubChem CID (GHK)
73587
PubChem CID (GHK-Cu)
71587328
Isolated
1973, human plasma albumin fraction

Two molecules, one name

GHK and GHK-Cu are routinely used interchangeably and they are not the same substance. GHK is the free tripeptide glycyl-histidyl-lysine at 340.38 Da. GHK-Cu is that peptide with a copper(II) ion bound, at 402.92 Da. The 62.54 Da difference is copper's atomic mass minus one proton, because binding displaces a hydrogen. Which one a paper studied matters, and the two are not always distinguished carefully in secondary writing.

Where it came from

Loren Pickart isolated the peptide from the albumin fraction of human plasma in 1973, in the course of work on a different question: why plasma from young donors, added to liver tissue from older donors, caused that tissue to synthesise proteins in a pattern more characteristic of younger tissue. The active fraction turned out to be a tripeptide. It carried the working name liver cell growth factor for a period, and is also indexed as prezatide.

Research material referenced

GHK-Cu 100mg, third-party HPLC tested

Buy GHK-Cu · £34.99

Why the copper matters

The histidine imidazole and the terminal amine give GHK a binding site with high affinity for copper(II), and the peptide is generally described as functioning as a copper carrier rather than as a peptide acting alone. That framing has a consequence often missed: much of the reported activity is attributed to delivering copper to enzymes that need it, which makes GHK-Cu as much a metal-delivery system as a signalling peptide. It also anchors the GLOW blend and the four-component KLOW stack.

What the literature reports

Published work describes effects on extracellular matrix biosynthesis, wound-repair models, antioxidant activity via copper delivery, and broad modulation of gene expression. Pickart and Margolina reported in BioMed Research International in 2015 that GHK modulates expression of more than 4,000 human genes, using the Broad Institute Connectivity Map. Nearly all of this is in vitro or animal work.

The declining-with-age observation

Plasma GHK concentrations are reported to fall with age, which is the observation the compound's anti-ageing framing rests on. It is a correlation in an observational measurement, and it does not establish that restoring the concentration reverses anything. A distinction that most writing about GHK-Cu does not make.

Regulatory position

GHK-Cu holds no marketing authorisation from the MHRA, EMA or FDA as a medicine. Copper tripeptide-1 is a recognised cosmetic ingredient name, which means topical products containing it are regulated as cosmetics. A different framework entirely from medicines, and not a route by which research material becomes a licensed product. Material supplied here is for laboratory research only.

Frequently asked questions

What is GHK-Cu's molecular weight?

402.92 Da for the copper complex, 340.38 Da for the free peptide. Sources frequently quote the free peptide's mass while labelling it as the complex.

Is GHK the same as GHK-Cu?

No. GHK is the free tripeptide; GHK-Cu is that peptide with copper(II) bound, displacing a proton. They differ by 62.54 Da.

Who discovered it?

Loren Pickart, in 1973, from the albumin fraction of human plasma while studying why young plasma altered protein synthesis in older liver tissue.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and reviewed by

William Heath · Editor, UK Peptides research library

William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.

More GHK-Cu (Copper Peptide) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.